Role of bempedoic acid in patients with hypercholesterolemia and statin intolerance


  • José Marcos Girardi
  • Antônio Alves do Couto



“bempedoic acid”, “ATP-citrate lyase”, hypercholesterolemia, “coronary artery disease”


introduction: Atherosclerotic cardiovascular disease is a leading cause of death and disability worlwide. The LDL-C causes atherosclerosis and therefore lowering the levels of these lipoproteins reduces the risk of acute myocardial infarction and other cardiovascular events. Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase and are the most cost-effective medicines for lowering LDL-C. Up to 80% of patients treated with statins do not achieve optimal LDL-C levels, explained by high baseline LDL-C levels, aggressive LDL-C treatment goals, lack of sufficient statin efficacy or drug intolerance. Objective: This review discusses the characteristics of statin intolerance and the mechanism of action, efficacy, and safety of Bempedoic Acid as a lipid-lowering agent. Methods: We searched PubMed, ScienceDirect, the Virtual Health Library and Latin American and Caribbean Health Sciences Literature for articles published in the last five years using the following health descriptors: “bempedoic” OR “ATP-citrate lyase” AND hypercholesterolemia AND “coronary artery disease”. Results: Bempedoic acid is a prodrug that is converted to its active form (bempedoyl-CoA) by the acyl-CoA synthetase-1 enzyme. Acts two steps upstream from HMG-CoA reductase, the target of statins, in the same metabolic pathway, representing an additional lipid-lowering therapy. Conclusions:Bempedoic Acid’s active metabolite is an effective treatment option, alone or in combination with statin or ezetimibe, to lower LDL-C and reduce hsCRP, which is a marker of systemic inflammation associated with future risk of cardiovascular events, suggesting an anti-inflammatory response. Outcomes and cost-effectiveness are currently being investigated in the CLEAR Outcomes study, with results expected in 2023.


-Ruscica M, Ferri N, Santos RD, Sirtori CR, Corsini A. Lipid Lowering Drugs: Present Status and Future Developments. Curr Atheroscler Rep. 2021 May 1 [cited 2022 Sep 3];23(5).

-Severino P, D’amato A, Pucci M, Infusino F, Adamo F, Birtolo LI, et al. Ischemic heart disease pathophysiology paradigms overview: From plaque activation to microvascular dysfunction. Int J Mol Sci. 2020 Nov 1 [cited 2022 Sep 3];21(21):1–30.

-Soppert J, Lehrke M, Marx N, Jankowski J, Noels H. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev [Internet]. 2020 Jan 1 [cited 2022 Sep 3];159:4–33.

-Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther [Internet]. 2022 Dec 1 [cited 2022 Sep 3];7(1).

-Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, et al. Management of Statin Intolerance in 2018: Still More Questions Than Answers. Am J Cardiovasc Drugs [Internet]. 2018 Jun 1 [cited 2022 Sep 3];18(3):157–73.

-Libby P, Bornfeldt KE. How Far We Have Come, How Far We Have Yet to Go in Atherosclerosis Research. Circ Res. 2020 [cited 2022 Sep 3];1107–11.

-Ugovšek S, Zupan J, Rehberger Likozar A, Sebestjen M. Influence of lipid-lowering drugs on inflammation: what is yet to be done? Arch Med Sci [Internet]. 2021 Mar 20 [cited 2022 Sep 3];

-Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther. 2021 Aug 1 [cited 2022 Sep 3];35(4):853–64.

-Kaddour R, Orabi B, Salam AM. Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update. J Drug Assess. 2020 Jan 1;9(1):129–44.

-Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54:134–51.

-Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.

-Kallapur A, Sallam T. Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms. Trends Cardiovasc Med. 2022 [cited 2022 Sep 3];

-Funabashi S, Kataoka Y, Hori M, Ogura M, Nakaoku Y, Nishimura K, et al. Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society. JACC Asia. 2021 Sep 1;1(2):245–55.

-Bonacina F, Da Dalt L, Catapano AL, Norata GD. Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis. Mol Aspects Med [Internet]. 2021 Feb 1 [cited 2022 Sep 3];77

-Keyes E, Grinnell M, Jacoby D, Vazquez T, Diaz DA, Werth VP, et al. Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. Int J Women’s Dermatology. 2021 Dec 1 [cited 2022 Sep 3];7(5):560–75.

-Rosenson RS. Existing and emerging therapies for the treatment of familial hypercholesterolemia. J Lipid Res. 2021 Apr 1 [cited 2022 Sep 3];62.

-Balla S, Ekpo EP, Wilemon KA, Knowles JW, Rodriguez F. Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care. Curr Atheroscler Rep. 2020 Oct 1 [cited 2022 Sep 3];22(10).

-Hindi NN, Alenbawi J, Nemer G. Pharmacogenomics variability of lipid-lowering therapies in familial hypercholesterolemia. J Pers Med. 2021 Sep 1 [cited 2022 Sep 3];11(9).

-Izar MC de O, Giraldez VZR, Bertolami A, Santos Filho RD Dos, Lottenberg AM, Assad MHV, et al. Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021. Arq Bras Cardiol. 2021 Oct 1 [cited 2022 Sep 3];117(4):782–844.

-Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocr Rev. 2022;43(4):611-653.

-Sposito AC, Carvalho LS, Cintra RM, et al. Brasilia Heart Study Group. Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis. 2009;207(1):191–4.

-Ballantyne CM, Banach M, Bays HE, Catapano AL, Laufs U, Stroes ESG, et al. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol. 2022 Jul 1;174:1–11.

-Banach M, Rizzo M, Toth PP, et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11:1–23.

-McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc. 2019 [cited 2022 Sep 3];8(24).

-Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol [Internet]. 2022 Jul [cited 2022 Sep 3];

-Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Lloyd-Jones D, et al. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc [Internet]. 2021 Oct 1 [cited 2022 Sep 3];96(10):2660–70.

-Lee CK, Liao CW, Meng SW, Wu WK, Chiang JY, Wu MS. Lipids and lipoproteins in health and disease: Focus on targeting atherosclerosis. Biomedicines [Internet]. 2021 Aug 1 [cited 2022 Sep 3];9(8).

-Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 Oct 1;277:195–203

-Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of Bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322:1780–8.

-Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8:e011662.

-Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019; 380:1022–32.

-Behbodikhah J, Ahmed S, Elyasi A, Kasselman LJ, De Leon J, Glass AD, et al. Apolipoprotein b and cardiovascular disease: Biomarker and potential therapeutic target. Metabolites. 2021 Oct 1 [cited 2022 Sep 3];11(10).

-Gunn LH, McKay AJ, Feng A, Louie MJ, Ballantyne CM, Ray KK. Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. Atheroscler Plus. 2022 Aug; 49:20–7.

-Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis: Current view and future perspective on lipoprotein modification treatment. Netherlands Hear J [Internet]. 2017 Apr 1 [cited 2022 Sep 3];25(4):231–42.




How to Cite

GIRARDI, J. M.; DO COUTO, A. A. Role of bempedoic acid in patients with hypercholesterolemia and statin intolerance. Journal Archives of Health, [S. l.], v. 4, n. 1, p. 108–119, 2023. DOI: 10.46919/archv4n1-011. Disponível em: Acesso em: 19 apr. 2024.